Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 13/20 | 0.66 |
| ▸ | MEN1 | O00255 | 10/20 | 0.66 |
| ▸ | CRHBP | P24387 | 3/20 | 0.66 |
| ▸ | CRHR2 | Q13324 | 3/20 | 0.66 |
| ▸ | DHFR | P00374 | 3/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.60 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5482792 | 1.00 | KMT2A (0.66) | KMT2AMEN1CRHBPCRHR2DHFR | |
| SCHEMBL5469474 | 0.90 | DHFR (0.63) | KMT2AMEN1CRHBPCRHR2DHFR | |
| SCHEMBL5469468 | 0.90 | DHFR (0.63) | KMT2AMEN1CRHBPCRHR2DHFR | |
| SCHEMBL5476060 | 0.90 | KMT2A (0.77) | KMT2AMEN1CRHBPCRHR2DHFR | |
| SCHEMBL5476058 | 0.90 | KMT2A (0.77) | KMT2AMEN1CRHBPCRHR2DHFR | |
| SCHEMBL5817698 | 0.87 | KMT2A (0.58) | KMT2AMEN1CRHBPCRHR2DHFR | |
| SCHEMBL5816953 | 0.85 | KMT2A (0.56) | KMT2AMEN1CRHBPCRHR2DHFR | |
| SCHEMBL5822283 | 0.85 | KMT2A (0.75) | KMT2AMEN1CRHBPCRHR2DHFR | |
| SCHEMBL26434393 | 0.85 | KMT2A (0.75) | KMT2AMEN1CRHBPCRHR2DHFR | |
| SCHEMBL5822284 | 0.85 | KMT2A (0.75) | KMT2AMEN1CRHBPCRHR2DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167488-A1 | Novel therapeutic use | LEO PHARMA A/S (DK) | 2007-07-19 | — | — | US | disclosed |
| US-20070167488-A1 | Novel therapeutic use | LEO PHARMA A/S (DK) | 2007-07-19 | — | — | US | disclosed |
| US-20070167488-A1 | Novel therapeutic use | LEO PHARMA A/S (DK) | 2007-07-19 | — | — | US | disclosed |
| WO-2006105796-A1 | NOVEL INDOLINONE DERIVATIVES | LEO PHARMA A/S (DK) | 2006-10-12 | — | — | WO | disclosed |
| EP-1696906-A1 | NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES | Leo Pharma A/S (DK) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005058309-A1 | NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES | LEO PHARMA A/S (DK) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167488-A1 | Novel therapeutic use | MAG, PMP22, MYT1 | KMT2A 1891/4885MEN1 1603/4885CRHBP 2528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.